Balaxi Pharmaceuticals Limited is a branded IPR-based pharma company with a primary focus on OTC segments, boasting a strong portfolio of branded generics catering to Latin America and Africa.

The company has strategically transitioned from an 'asset light' to 'asset right' model by setting up its first manufacturing unit in Hyderabad, aimed at boosting its production capabilities and market presence.

Despite revenue decline in Q2 FY26 due to market demand pressure and logistics issues, Balaxi maintained a gross profit margin above 48%, showcasing the resilience of its branded generics portfolio.

Balaxi has over 935 product registrations across seven countries with plans for further expansion, enhancing its global footprint and therapeutic coverage.

The company is implementing centralized digital systems for procurement and regulatory management to streamline operations, expedite market access, and control regulatory processes.